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ABSTRACT
Background Asthma affects 300 million people
worldwide. In asthma, the major cause of morbidity
and mortality is acute airway narrowing, due to airway
smooth muscle (ASM) hypercontraction, associated with
airway remodelling. However, little is known about the
transcriptional differences between healthy and asthmatic
ASM cells.
Objectives To investigate the transcriptional
differences between asthmatic and healthy airway
smooth muscle cells (ASMC) in culture and investigate
the identiﬁed targets using in vitro and ex vivo
techniques.
Methods Human asthmatic and healthy ASMC grown
in culture were run on Affymetrix_Hugene_1.0_ST
microarrays. Identiﬁed candidates were conﬁrmed by
PCR, and immunohistochemistry. Functional analysis was
conducted using in vitro ASMC proliferation, attachment
and contraction assays and ex vivo contraction of mouse
airways.
Results We suggest a novel role for latrophilin (LPHN)
receptors, ﬁnding increased expression on ASMC from
asthmatics, compared with non-asthmatics in vivo and in
vitro, suggesting a role in mediating airway function.
A single nucleotide polymorphism in LPHN1 was
associated with asthma and with increased LPHN1
expression in lung tissue. When activated, LPHNs
regulated ASMC adhesion and proliferation in vitro, and
promoted contraction of mouse airways and ASMC.
Conclusions Given the need for novel inhibitors of
airway remodelling and bronchodilators in asthma, the
LPHN family may represent promising novel targets for
future dual therapeutic intervention.
INTRODUCTION
Asthma is a chronic inﬂammatory disease affecting
300 million people worldwide. With the incidence
of asthma on the rise1 2 and a proportion of
patients remaining uncontrolled by current therap-
ies,3 there is an unmet need to identify new thera-
peutic targets. In asthma, the major cause of
morbidity and mortality is acute airway narrowing.
This is in part the result of airway smooth muscle
(ASM) hypercontraction, a feature speciﬁc to
asthma.4–6 However, despite numerous studies
focusing on the aberrant nature of asthmatic ASM
cells, including increased proliferation, little is
known about the receptors and pathways which
may contribute to this hypercontractile phenotype.
Latrophilins (LPHNs) are a novel family of
receptors previously thought to be brain speciﬁc,7
but with unknown physiological function.8 LPHNs
are a unique class of G protein-coupled receptors,
which can also act to facilitate cell adhesion.9
Originally identiﬁed for their ability to bind to
α-latrotoxin (α-LTX), a toxin produced by the
Latrodectus genus of spiders,7 they are best charac-
terised for their role in the release of neurotrans-
mitters (including acetylcholine (ACh)) from
sensory and motor neurons, and also for the
release of insulin from endocrine cells.
In this study, we compared gene expression pro-
ﬁles between asthmatic and healthy airway smooth
muscle cells (ASMC) grown in vitro. Through this
analysis, we identiﬁed the enhanced expression of
LPHN1 and 3 in asthmatic ASMCs. Using expres-
sion quantitative trait locus (eQTL) analysis in lung
tissue, the expression of LPHN1 was identiﬁed to
be enhanced by a single nucleotide polymorphism
(SNP) overrepresented in the asthmatic population.
To demonstrate the role and function of the LPHN
Key messages
What is the key question?
▸ What is the speciﬁc role of latrophilins in
airway smooth muscle cell phenotype?
What is the bottom line?
▸ This study found an increased expression of
members of the latrophilin family of receptors in
patients with asthma through comparison of
healthy with asthmatic human airway smooth
muscle (ASM) cells in culture, with the bottom
line being that latrophilins may contribute to ASM
contraction as well as adhesion and proliferation
and their increased expression in asthmatic ASM
may affect the asthma phenotype.
Why read on?
▸ This study provides novel insights into the
transcriptional and functional differences
between asthmatic and healthy ASM cells.
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family in ASM, we tested known ligands and agonists in in vitro
human cellular assays and ex vivo mouse airways. Ligands for
LPHN receptors were able to directly and indirectly contract
ASM and to contribute to the processes leading to remodelling
of the airway wall present in asthma by promoting both ASM
proliferation and attachment.
MATERIALS AND METHODS
ASMC isolation/culture and microarray analysis
Human ASMC were obtained from bronchial biopsies and
explanted lungs from doctor diagnosed asthmatic patients (n=3)
and healthy controls (n=3). ASMC were isolated and grown in
culture as previously described.10
Total cellular mRNA was isolated using the Qiagen total RNA
isolation kit (Qiagen, Doncaster, Victoria, Australia). Samples
were labelled and run on an Affymetrix (Santa Clara,
California, USA) GeneChip Human Gene 1.0 ST Arrays accord-
ing to the manufacturer’s instructions (GSE63383). Microarray
analysis was conducted using R software V.3.02, using the
Bioconductor-limma package, and normalised using Robust
Multi-array Average.
Validation of microarray results
The validation of the microarray results was undertaken at a
transcriptional (quantitative real-time PCR) and translational
(immunohistochemistry) level and the analyses are described in
detail in the online supplementary materials.
Single SNP and lung eQTL analysis
Single SNP analysis was conducted on polymorphisms within
the LPHN1 and LPHN3 genes using the Dutch Asthma
genome-wide association study (GWAS) (DAG) cohort, a cohort
characterised by the presence of a doctor diagnosis for asthma
and bronchial hyper-responsiveness.11 12 Associations between
LPHN1 and LPHN3 polymorphisms and the phenotype of
asthma (deﬁned by doctor diagnosis) and severity of bronchial
hyperresponsiveness BHR of asthmatics (slope of BHR) were
conducted.
SNPs signiﬁcantly associated with risk of asthma were then
explored in a large eQTL lung tissue dataset,13 to determine
whether they played a functional role in LPHN gene expression.
This lung eQTL dataset consisted of individuals with both
genome-wide genotyping and microarray expression data from
three sites of recruitment, University of Groningen, Laval
University, University of British Columbia (UBC) (n=1095).
Genome-wide gene expression and genotyping proﬁles were
obtained using a custom Affymetrix array, Gene Expression
Omnibus platform GPL10379 (GSE23546), and the Illumina
Human1M-Duo BeadChip array, respectively. Standard quality
controls were performed as described previously.13
Human and animal tissue ethics
Isolated human airway tissue was obtained from explanted and
resected lungs and post mortem organ donors with ethical
approval from The University of Sydney and participating hospi-
tals (Concord Repatriation General Hospital, Sydney South West
Area Health Service and Royal Price Alfred Hospital). All patients
provided written informed consent or, in the case of post mortem
samples, consent was obtained from the next of kin. Demographic
details of the patients used in this series of experiments are shown
in online supplementary table S1. For cell contraction measure-
ments, primary human ASMC were obtained with approval from
the Gift of Hope Foundation, Illinois, USA. Approval for mouse
tissue usage was through the University of Melbourne Animal
Ethics Committee (approval number: #1212485). Non-tumour
lung tissues were collected for the eQTL analysis from patients
who underwent lung resection surgery at three participating sites:
Laval University, University of Groningen and UBC.13
Functional analysis
To identify the function of the LPHN receptors, the effects of
the known LPHN ligands ﬁbronectin leucine rich transmem-
brane protein 3 (FLRT3) and α-LTX were explored in immorta-
lised airway smooth muscle cell (IASMC) proliferation (manual
cell count) and attachment assays. To assess potential
LPHN-induced contraction, the effects of FLRT3 and α-LTX on
trachea and bronchi from Balb/C mice were measured ex vivo
by myography. Measurements of cell contraction were con-
ducted using contractile force screening.14 Brieﬂy, cells were
cultured to conﬂuence on custom elastic substrates (polyacryl-
amide, stiffness=1.8 kPa) prepared within 96-well plates. In
each well, the average contractile stress (in Pascal) was measured
at baseline and following treatment(s). Data are reported as the
force-response ratio, that is, the ratio of treatment to baseline
contraction. Methods are described in detail in the online
supplementary material.
Densitometry and statistical analysis
Densitometric analyses of western immunoblots were conducted
using Carestream Molecular Imaging Software using the mean
intensity region of interest (ROI) for each band (Carestream
Health, Rochester, New York, USA). For western immunoblot
experiments, ROIs were compared with glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in the same sample on the
same membrane as an internal control. Statistical tests and
graph plotting were conducted using GraphPad Prism 6
(GraphPad Software, La Jolla, California USA). A probability
(p) value of <0.05 was considered statistically signiﬁcant.
RESULTS
Differential gene expression between asthmatic
and healthy ASMC
To evaluate differential expression between healthy and asthmatic
ASMC, primary cells from healthy (n=3) and asthmatic (n=3)
people were grown in vitro and the baseline expression proﬁles
were measured using GeneChip Human Gene 1.0 STArray; com-
parisons were conducted using limma statistical package for R
(V.3.0.2). We identiﬁed 13 genes upregulated and 40 genes down-
regulated in asthmatic ASMC compared with healthy controls
(false discovery rate (FDR) <0.5, fold change±2). The top 10
upregulated and downregulated genes are noted in online supple-
mentary tables S2 and S3, respectively. A hierarchical cluster ana-
lysis is illustrated in ﬁgure 1A. Among the top genes enhanced in
asthmatic ASMC were tropomyosin (TPM1), actin, gamma 2,
smooth muscle, enteric (ACTG2) and LPHN3. While TPM1 and
ACTG2 have been previously characterised for their roles in
ASMC function, LPHN3 was a newly identiﬁed candidate.
Gene set enrichment analysis of genes differentially
expressed in asthmatic ASMC
To identify key pathways that may be altered between asthmatic
and healthy ASMC, gene set enrichment analysis (GSEA) ana-
lysis was conducted on the microarray dataset to extend the
gene list. As biologically relevant to the cells studied, genes
involved in the regulation of muscle and heart contraction were
increased in asthmatic ASMC relative to healthy controls (GSEA
FDR q<0.031) (ﬁgure 1B). An overview of all enriched path-
ways can be seen in online supplementary table S4.
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Asthmatic ASMC express higher levels of LPHN1 and 3
qPCR measurements of LPHN family members showed that
mRNA levels of both LPHN1 and 3 were signiﬁcantly increased in
asthmatic ASMCs compared with healthy (p=0.010 and p=0.002,
respectively, Mann-Whitney test) (ﬁgure 2A, B), whereas no differ-
ence was found with LPHN2 (data not shown). ASM-speciﬁc stain-
ing for LPHN3 was detected, using immunohistochemical staining
of bronchial biopsies, with cell density-independent elevation in
patients with asthma compared with healthy controls (p=0.010,
Mann-Whitney test) (ﬁgure 2C, D).
Association of LPHN1 and LPHN3 SNPs with asthma
Two polymorphisms for LPHN1 and 33 polymorphisms for
LPHN3 were available for analysis on the Illumina Chips, and
associations with the asthma phenotype were investigated.
A single SNP in LPHN1 (rs3810256) was identiﬁed, with the
minor allele increasing the risk of asthma (FDR=0.016) (table 1).
Associations between LPHN1 and LPHN3 polymorphisms and
severity of bronchial hyper-responsiveness in asthmatics were
conducted in the DAG cohort; however, no associations were
found (see online supplementary table S5).
rs3810256 polymorphism is associated with LPHN1 gene
expression
To further quantify the role of the rs3810256 SNP on LPHN1
gene expression, eQTL meta-analysis on three cohorts was con-
ducted to determine if this SNP was associated with mRNA
expression levels of LPHN1 in human lung tissues. The eQTL ana-
lysis identiﬁed a single probe within LPHN1 which had increased
expression associated with the rs3810256 minor allele (identiﬁed
to increase the risk of asthma) in the Laval cohort (β±SE=0.08
±0.02, p=0.001), and a trend towards association was seen in the
Groningen cohort (β±SE=0.05±0.03, p=0.16) and the UBC
cohort (β±SE=0.04±0.03, p=0.18) (table 2). Meta-analysis of all
three cohorts identiﬁed an overall signiﬁcant effect of the
rs3810256 minor allele on increased expression of the LPHN1
gene (β±SE=0.06±0.02, p<0.001).
FLRT3 promoted adhesion and proliferation of asthmatic
ASMC via LPHN3
The functional role of LPHN3 in ASMC was investigated using its
known endogenous ligand, FLRT3. FLRT3 (10 ng/mL) enhanced
adhesion of IASMC cells (p=0.037, Friedman test, Dunn’s correc-
tion) and speciﬁcally enhanced proliferation of asthmatic IASMC
Figure 1 Microarray analysis of
asthmatic and healthy airway smooth
muscle cells (ASMC). (A) Hierarchy
cluster analysis comparing asthmatic
(n=3) and healthy (n=3) ASMC
expression proﬁles with the rows
identifying genes with fold change >
±2, p<0.05. (B) Enrichment of genes
involved in the regulation of muscle
contraction associated with genes
upregulated in asthmatic ASMC
relative to healthy controls (GSEA false
discovery rate (FDR) <0.05). The
coloured bar represents genes ranked
based on their differential expression
between asthmatic and healthy ASMC.
Vertical bars represent the running
GSEA enrichment score and location
(in the ranked gene list) of genes
involved in the regulation of muscle
contraction.
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cells (p=0.042, Friedman test, Dunn’s correction) (ﬁgure 3A, B).
Proliferation was blocked in asthmatic IASMC by either the phos-
phoinositide 3 kinase inhibitor, LY294002 (3 μM), or a trend
towards signiﬁcance with the mitogen-activated protein kinase
kinase (MEKK) inhibitor, PD98059 (10 μM) (p=0.002 and
p=0.076, respectively, Friedman test, Dunn’s correction) (ﬁgure
3B), which blunted extracellular regulated kinase (ERK) phosphor-
ylation (ﬁgure 3C, D).
Activation of LPHN1 and 3 caused contraction in mouse
airway preparations
Mouse tracheal and bronchial tissues were mounted on myo-
graphs at an optimum length for maximal force generation in
response to the potassium depolarising solution (KPSS).
Thereafter, the mean active force generated during two contrac-
tions induced by ACh 10−4 M was determined; 7.2±0.7 and
6.1±0.7 mN for trachea (n=15) and bronchi (n=12), respect-
ively. Only tissues responding to both KPSS and ACh were
included. These responses were used to normalise contractile
responses induced via LPHN receptors.
Exposure of trachea or bronchi to α-LTX elicited ∼40% of
the ACh maximum response in these tissues (ﬁgure 4A–C). Both
the ACh and α-LTX-induced contractions were blocked by the
muscarinic antagonist atropine (3 μM, p=0.036, Mann-Whitney
test, ﬁgure 4B, C).
At low concentrations (10−11–10−9.5 M), the LPHN3 ligand,
FLRT3, had no effect on basal tone in isolated tracheal prepara-
tions with or without epithelium (control, ﬁgure 4E). However,
FLRT3 elicited contraction at the highest concentrations tested
(10−8.5 M) in intact trachea in the presence of EP2/4 antagonists
(+ AH6704/L161982) (ﬁgure 4D, E). This contraction to FLRT3
was abolished when the epithelium was removed (ﬁgure 4E).
Activation of LPHN3 but not LPHN1 caused contraction in
human ASMC
The direct effects of α-LTX and FLRT3 were assessed using the
experimental approach of contractile force screening.14 The
baseline force was used to normalise contractile responses
induced by α-LTX, FLRT3 and histamine. Exposure of ASMC
to FLRT3 (1.75 and 17.45 nM) induced a sustained contraction
for 30 min (p<0.05), which was then relaxed with the addition
of isoprenaline. In contrast, exposure to α-LTX (0.1 and 1 nM)
did not induce contraction (p>0.05). α-LTX (10 nM) had a
cytotoxic effect on ASMC under subconﬂuent conditions and
was unable to be run in this cellular model.
DISCUSSION
In this study, genome-wide gene expression was used as a
hypothesis generating method to identify genes differentially
expressed between asthmatic and healthy ASMC. The gene
expression proﬁle from the subsequent analysis differed between
the asthmatic and healthy phenotypes, with genes associated
with muscle contraction being enhanced in asthmatic ASMC.
The gene candidate LPHN3 identiﬁed in the microarray analysis
was veriﬁed in a larger patient group at both the transcriptional
and translational levels. The expression levels of the other
LPHN family members were measured, with LPHN1 also
increased in asthmatic ASMC at the transcriptional level. A
single SNP (rs3810256) in LPHN1 was found to associate with
an increased risk of asthma. Lung eQTL analysis identiﬁed that
the rs3810256 SNP minor allele was associated with increased
expression of LPHN1, this direction of effect is consistent with
LPHN1 upregulation in asthmatics.
The function of the LPHN1 and 3 receptors were explored
using a known agonist α-LTX and an endogenous LPHN3 ligand
FLRT3. FLRT3 facilitated adhesion and proliferation of ASMC
Figure 2 ASMC expression of
latrophilins in cells from asthmatic and
healthy airways. ASMC were grown to
conﬂuence in growth media (DMEM,
5% FBS and 1% antibiotics) and
quiesced (DMEM, 0.1% BSA and 1%
antibiotics) for 72 hours and total
mRNA was extracted. qPCR of
latrophilin family members LPHN1 (A)
and 3 (B) comparing asthmatic (n=15)
and healthy (n=6) ASMC. (C)
Immunohistochemistry for LPHN3,
comparing healthy (n=6) and asthma
(n=11) donor bronchial sections
(representative images). Speciﬁc
staining was detected using a chemical
chromophore 3,3’-diaminobenzidine
(DAB) (brown) and cell nucleus was
counterstained with haematoxylin
(blue)(scale 100 μm). (D)
ASMC-speciﬁc LPHN3 in healthy and
asthma donor sections were quantiﬁed
and compared using computerised
image analysis. Data are expressed as
mean±SEM. Statistical analysis used
was Mann-Whitney test. ASMC, airway
smooth muscle cell; BSA, bovine serum
albumin; DMEM, Dulbecco’s Modiﬁed
Eagle Medium; E, epithelium; FBS,
foetal bovine serum; L, lumen; M,
airway smooth muscle; ROI, region of
interest.
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with the latter being enhanced only in patients with asthma.
Stimulation with α-LTX contracted tracheal and bronchial tissues
from mice; however, this was found to be an indirect response
mediated through the release of ACh as indicated by blocking the
response with the muscarinic antagonist, atropine. FLRT3 caused
contraction of both trachea in the presence of prostaglandin
receptor (subtypes EP2/4) antagonists and ASMC in contraction
assays conducted in the absence of epithelium.
GSEA analysis identiﬁed that genes which regulate muscle
contraction were overrepresented in the grouping of genes over-
expressed in asthmatic ASMC relative to healthy controls. The
literature is currently divided on whether the hypercontractility
seen in asthmatic ASMC has an environmental or intrinsic
origin. However, this ﬁnding may begin to elucidate the mech-
anism underlying the increased contraction of asthmatic ASMC
to contractile agents relative to healthy controls found in some
Table 1 SNPs for LPHN1 and LPHN3 associations with asthma
CHR BP SNP TA OR OR(R) P P(R) I FDR
LPHN1
19 14120846 rs3810256 A 1.348 1.348 0.008 0.008 0 0.016
19 14159442 rs2420416 G 1.032 1.032 0.676 0.676 0 1
LPHN3
4 62327627 rs12509742 A 0.986 0.986 0.829 0.829 0 1
4 62330503 rs2345043 T 0.982 0.982 0.788 0.788 0 1
4 62352873 rs1450903 G 0.848 0.846 0.095 0.356 70.21 1
4 62354238 rs10517547 A 0.962 0.960 0.665 0.808 71.98 1
4 62376287 rs11734607 T 1.010 1.009 0.895 0.917 29.69 1
4 62380952 rs2345041 A 1.083 1.083 0.364 0.364 0 1
4 62401922 rs2015569 T 0.899 0.898 0.297 0.508 60.12 1
4 62409295 rs7667328 G 0.978 0.983 0.839 0.934 71.67 1
4 62409469 rs10446786 G 1.008 1.007 0.915 0.932 24.10 1
4 62416032 rs13110933 C 1.069 1.069 0.314 0.314 0 1
4 62422136 rs6551665 G 0.907 0.907 0.150 0.272 41.51 1
4 62422269 rs6846033 C 0.980 0.980 0.801 0.801 0 1
4 62430979 rs9683662 T 1.029 1.029 0.691 0.691 0 1
4 62436915 rs6858066 G 1.039 1.039 0.563 0.621 28.83 1
4 62441865 rs11131347 T 0.928 0.928 0.246 0.246 0 1
4 62444465 rs1470724 C 1.093 1.093 0.227 0.227 0 1
4 62446070 rs6551666 C 1.000 1.002 0.999 0.990 60.75 1
4 62471863 rs10517549 G 1.016 1.016 0.831 0.831 0 1
4 62483323 rs734644 T 1.027 1.027 0.729 0.729 0 1
4 62499334 rs1450896 A 0.776 0.775 0.182 0.318 44.74 1
4 62501063 rs995447 C 1.046 1.046 0.729 0.729 0 1
4 62513128 rs1510925 G 1.062 1.064 0.473 0.601 50.00 1
4 62517697 rs1397545 A 1.052 1.052 0.646 0.646 0 1
4 62521660 rs1397543 T 1.041 1.043 0.633 0.724 50.03 1
4 62528085 rs1397548 A 1.062 1.062 0.416 0.416 0 1
4 62533752 rs17292128 C 1.207 1.207 0.034 0.034 0 1
4 62539254 rs10017760 A 1.023 1.023 0.797 0.797 0 1
4 62544980 rs2271339 G 1.073 1.072 0.352 0.547 56.20 1
4 62550048 rs13115125 G 1.044 1.043 0.511 0.765 78.09 1
4 62566026 rs1510920 C 0.852 0.839 0.281 0.479 63.93 1
4 62584757 rs6827266 T 0.950 0.950 0.431 0.431 0 1
4 62597619 rs1397546 C 0.918 0.914 0.198 0.554 80.54 1
4 62606392 rs11736888 T 1.016 1.016 0.839 0.839 0 1
BP, base pair; CHR, chromosome; FDR, false discovery rate; I, heterogeneity of samples; LPNH, latrophilin; R, random effect; SNP, single nucleotide polymorphism; TA, tested allele bold
indicates SNPs associated with asthma.
Table 2 eQTL analysis of rs3010256 in LPHN1
Probe SNP TA (ref 36.3) Start probe (ref 36.3) End probe Cohort β SE p Value
LPHN1 rs3810256 A 14119550 14177997 Groningen 0.048 0.034 0.160
Laval 0.076 0.023 1.000E-03
UBC 0.038 0.028 0.175
Meta 0.058 0.016 2.330E-04
eQTL, expression QTL; LPNH, latrophilin; meta, combined analysis of Groningen, Laval and UBC cohorts; SNP, single nucleotide polymorphism; TA, tested allele; UBC, University of
British Columbia.
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studies independent of environmental inﬂuences that promote
BHR, perhaps driven by genetic or epigenetic factors.15 16
ASMC from patients with asthma were found to have an
increased rate of attachment to FLRT3. The FLRT3-LPHN3
interaction may assist the docking of other cell types expressing
FLRT3 on their surfaces to ASMC, a mechanism that is aug-
mented in the asthmatic airway. Such a system has been reported
in cell lines overexpressing LPHN3 and FLRT3.9 Previously the
expression of FLRT3 has been shown to be upregulated follow-
ing stimulation with lipopolysaccharide and by Legionella pneu-
mophila infections in a number of inﬂammatory cells.17–19
Therefore, it is tempting to postulate that the increased presence of
LPHN3 receptors on asthmatic ASMC may enhance the docking
of inﬂammatory cells to ASMC during inﬂammatory episodes.
FLRT3 induced proliferation of asthmatic ASMC (∼142%) is
comparable with the induction of proliferation by platelet-
derived growth factor subunit B (PDGF-BB) (∼150%) (a well-
known ASMC proliferation stimulus)20 following 72H treat-
ment in serum-reduced medium. This proliferation of asthmatic
ASMC was blocked following the inhibition of the mitogen-
activated protein kinase (MAPK) pathway. As the activation of
the MAPK pathway, through ERK1/2 phosphorylation, is
enhanced in asthmatic ASMC,21 it is therefore probable that the
FLRT3-LPHN3 interaction contributes to enhanced proliferation
of asthmatic ASMC.22 23 These results suggest that LPHN3 may
be a potential target for the regulation of remodelling in the
asthmatic airway.
In previous studies in non-airway tissues, α-LTX induced
release of ACh, a potent contractile agent of ASM;24–26 in skel-
etal muscle preparations, ACh release from small synaptic vesi-
cles in response to α-LTX led to contraction.26 27 Since the
response to both ACh and α-LTX in the current study was
ablated by the muscarinic antagonist, it appears that α-LTX
mediated airway contraction through the release of Ach by
Figure 3 FLRT3 effect on IASMC attachment and proliferation in asthma and healthy donor cells. (A) IASMC were grown to conﬂuence in growth
medium (DMEM, 5% FBS and 1% antibiotics) and quiesced (DMEM, 0.1% BSA and 1% antibiotics) for 24 hours, seeded at 16 000 ASMC per well
in quiescing media and left for 2 hours at 37°C in 5% CO2 (n=7). Attached cells were stained with toluidine blue measured by spectrophotometry at
absorbance 595 nm. Data are expressed as mean±SEM. Friedman test, Dunn’s correction was used to compare control to other treatments. IASMC
proliferation was measured by manual cell count following quiescing for 72 hours and then treatment with (B) quiescing medium (control), FLRT3
(10 ng/mL), FLRT3 (10 ng/mL)+PD98059 (10 μM) and FLRT3 (10 ng/mL) +LY294002 (3 μM) for 72 hours (asthmatics, n=6 and healthy donors, n=6).
Data are expressed as mean±SEM. Friedman test, Dunn’s correction was used to compare (#=p<0.05 compared with control, ‡=p<0.05 compared
with FLRT3). (C) ASMC were seeded and grown to conﬂuency and quiesced for 72 hours and then treated with quiescing medium (control), FLRT3
(10 ng/mL), FLRT3 (10 ng/mL)+PD98059 (10 μM) and FLRT3 (10 ng/mL)+LY294002 (3 μM). (D) Representative western immunoblot for pERK1/2,
total ERK1/2 and GAPDH H (n=8) (D) Densitometric analysis of ERK1/2 western. Data are expressed as mean±SEM. Friedman test, Dunn’s correction
was used to compare. ANOVA, analysis of variance; ASMC, airway smooth muscle cells; BSA, bovine serum albumin; DMEM=Dulbecco’s Modiﬁed
Eagle Medium; ERK1/2, extracellular signal-regulated protein kinases 1 and 2; FBS, foetal bovine serum; FLRT3, ﬁbronectin leucine rich
transmembrane protein 3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IASMC, immortalised airway smooth muscle cells; LY, LY294002; PD,
PD98059; pERK1/2, phosphorylated extracellular signal-regulated protein kinases 1 and 2.
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cholinergic nerves28 and/or the epithelium,29 rather than by the
direct activation of LPHN1 on the ASMC. This was further
highlighted with the lack of contraction of ASMC to α-LTX in
the cell contraction assay which was conducted in the absence
of cholinergic nerves and the epithelium.
The effects of α-LTX on airway contraction, reported here for
the ﬁrst time, provide pivotal experimental evidence elucidating
the mechanism underlying the breathing difﬁculties, including
bronchospasm and chest tightness, associated with bites from the
widow genus spiders.30 Furthermore, these data support the use
of atropine in addition to traditional anti-venom therapy to treat
airway distress associated with widow genus spider bites.
Selective activation of LPHN3 by FLRT3 in mouse trachea
also resulted in contraction. However, this was only evident in
trachea with an intact epithelium, and when the potential con-
tribution of prostaglandin E2 (PGE2), an endogenous mediator
that promotes airway relaxation31 was also inhibited. Since a
consistent contractile response to FLRT3 was obtained in tissues
treated with EP2/EP4 antagonists at concentrations previously
shown to inhibit PGE2-mediated relaxation in mouse intrapul-
monary airways,32 it appears that FLRT3-mediated contraction
may be physiologically opposed by endogenous PGE2 promot-
ing relaxation. The lack of response to FLRT3 following epithe-
lial removal under these conditions suggests that it may facilitate
the release of contractile factors from the epithelium leading to
contraction of ASM. In contrast to these ﬁndings in mouse
airways, FLRT3 induced ASMC contraction in the cell contrac-
tion assay despite the absence of the epithelium. Together these
results suggest that FLRT3 promotes contraction indirectly via
the epithelium in mouse trachea and directly in human ASMC.
Since FLRT3 represents the endogenous ligand for LPHN3,
the effects observed in the present study may have physiological
implications with respect to asthma in terms of increasing bron-
chial tone. This will need to be investigated further using select-
ive antagonists to the LPHN receptors. Given that the
relaxation signalling cascade may be impaired in asthma, activa-
tion of the LPHN3 receptor may account in part for the
increase in airway contractility in asthma.
The main strength of this study was the multidisciplinary
approach used to identify a novel gene target using mass screen
approaches including both microarray analysis and candidate
SNP/eQTL analysis followed by the functional interrogation of
Figure 4 The effect of α-LTX and FLRT3 on mouse tracheal and bronchial preparations and airway smooth muscle cells (ASMC) contraction assays
Male Balb/C mice were killed by intraperitoneal injection of 0.4 mL sodium pentobarbitone (60 mg/mL) at 6–8 weeks of age. After an equilibration
period of 30 min, tissues were contracted to KPSS at differing tensions (1.2, 1.5, 1.8 mN for trachea; 1.0, 2.0, 3.0 mN for bronchi) to determine the
optimal resting tension for each tissue that corresponded to the highest KPSS response. Tissues were then contracted to ACh (10−4 M) twice to
determine the effect of maximum muscarinic receptor activation. α-LTX- (10 nM) induced contraction of trachea (A and C) and bronchi (D) in the
absence (white bars) and presence (black bars) of atropine (3 μM), n=3–5. B and E) Concentration-dependent effect of FLRT3 (10–3000 pM) in
mouse trachea in the presence (open circles, n=7) or absence of epithelium (light grey circles, n=4) or EP2 and EP4 antagonists (AH6809 3 μM and
L-161982 1 μM) in the presence (black circles, n=6) or absence of epithelium (dark grey circles, n=4). Statistical analysis used was Mann-Whitney
test. (F) Single cell contraction assay of ASMC treated with LTX (0.1, 1 nM), FLRT3 (1.75, 17.45 nM) or histamine (1 mM) for 30 min and then
relaxed with isoprenaline (10 mM) (n=10). Statistical analysis used was Mann-Whitney test. All data are expressed as mean±SEM. Ach,
acetylcholine; α-LTX, α latrotoxin, FLRT3, ﬁbronectin leucine rich transmembrane protein 3.
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the candidate using in vitro/ex vivo models. There were some
limitations to this study that should be acknowledged. First, the
low numbers of subjects screened and the less stringent FDR in
the initial microarray analysis. The impact of this limitation was
overcome by the qPCR veriﬁcation of the identiﬁed candidates
in an expanded group of asthmatic and healthy ASMC. Second,
as the microarray analysis was conducted in vitro it is possible
that the gene expression differences may be due to senescence
or differences in the rate of proliferation and dedifferentiation
in culture. However, to limit this effect all patient cells included
in the microarray arrays were grown under the same conditions
and at the same passage number. Third, as both LPHN1 and
LPHN2 have the ability to interact with α-LTX, the effect of
LPHN2 on the ASMC was unable to be excluded as a factor
which may have contributed to the in vitro functional analysis.
Finally, the rs3810256 risk allele was identiﬁed to be signiﬁcantly
associated with increased expression of LPHN1 in the
meta-analysis of all three cohorts; individual analysis of the UBC
and Groningen cohorts was not found to be signiﬁcant, yet the
directions of the effects were the same. One of the possible
reasons for this ﬁnding may have been the source of the lung
tissue used for expression analysis. The UBC and Groningen
cohorts were considerably more heterogeneous (wider variety of
lung diseases) than the Laval cohort. As the amount of ASMC in
each patient can vary signiﬁcantly depending on the underlying
disease phenotype, this may have affected the level of LPHN1
mRNA detected irrespective of the SNP genotype.
This study identiﬁed for the ﬁrst time, to our knowledge, the
expression of LPHN1 and LPHN3 in ASMC, and found these
to be enhanced in patients with asthma. The differential effects
of FLRT3 in asthmatic and healthy airways may potentiate both
airway remodelling and contraction in asthma. Functional ana-
lyses suggest a modest role of LPHN receptors in ASM adher-
ence and proliferation. A similar modest effect of direct
activation of ASM LPHN receptors on ASM cell contractility
was observed, although a more robust effect of LPHN receptor
antagonism was noted in ASM tissue, likely due to effects on
epithelia and neurotransmission. The airway contraction
observed in the presence of α-LTX, mediated through the
release of ACh, identiﬁed the mechanism underlying bronchial
spasms and chest tightness associated with bites from the widow
genus spiders. On the basis of these ﬁndings, we suggest that
blocking of the LPHN receptors in the airways may provide
novel targets for future therapeutics for asthma.
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